← Back to news
Clinical

Novo Nordisk's CagriSema Heads to FDA Review — Decision Expected by October 2026

#CagriSema#Novo Nordisk#cagrilintide#semaglutide#GLP-1#amylin#obesity#FDA

Novo Nordisk's next-generation obesity therapy CagriSema is now under active FDA review, with a regulatory decision anticipated around October 2026. The drug, a fixed-dose combination of cagrilintide (a long-acting amylin analogue) and semaglutide (a GLP-1 receptor agonist), represents the Danish pharma giant's bid to leapfrog its own blockbuster Wegovy by targeting two distinct hormonal pathways simultaneously.

The company filed its New Drug Application (NDA) in December 2025, supported by data from the comprehensive REDEFINE clinical trial program.

What the Trials Show

The REDEFINE 1 Phase 3 trial delivered headline results that exceeded semaglutide monotherapy:

  • 22.7% average body weight reduction from baseline over 68 weeks
  • 91.9% of participants achieved at least 5% weight loss (vs. 31.5% on placebo)
  • Favorable tolerability profile consistent with the known GLP-1 class effects — nausea, diarrhea, and constipation were the most common adverse events, mostly mild to moderate and concentrated in the dose-escalation phase

The dual-mechanism approach works because amylin and GLP-1 regulate appetite through complementary brain circuits. Cagrilintide acts primarily on the area postrema and the hypothalamus to slow gastric emptying and reduce food intake, while semaglutide activates GLP-1 receptors involved in satiety signaling and glucose metabolism.

Competitive Landscape

CagriSema enters a rapidly crowding obesity market:

  • Eli Lilly's retatrutide, a triple GIP/GLP-1/glucagon receptor agonist, recently posted 28.7% weight loss in Phase 3 — potentially outperforming CagriSema on raw efficacy.
  • Oral GLP-1s like Lilly's newly approved Foundayo (orforglipron) offer convenience advantages that could reshape market dynamics.
  • Compounded semaglutide still captures significant market share among cost-sensitive patients, though FDA enforcement is tightening.

Novo Nordisk's bet is that CagriSema's dual mechanism will deliver superior weight loss and metabolic outcomes compared to semaglutide alone, justifying a premium price point and differentiating it from Wegovy in a market where Lilly is gaining ground.

What's Next

The FDA's Prescription Drug User Fee Act (PDUFA) target date is expected around October 2026. If approved, CagriSema would become the first fixed-dose combination of a GLP-1 agonist and an amylin analogue — a new therapeutic class for weight management. Novo Nordisk has indicated it is preparing manufacturing capacity to avoid the supply shortages that plagued Wegovy's early launch.